Table 2.

Changes in visual functions and subfoveal choroidal thickness in AZOOR and fellow eyes.

Case	Treatment	Best-corrected visual acuity (logMAR)			Average threshold (dB)			Subfoveal choroidal thickness (μm)
								AZOOR eyes			Fellow eyes
		Baseline	3 M	6 M	Baseline	3 M	6 M	Baseline	3 M	6 M	Baseline	3 M	6 M
1	None	0.3	−0.1	−0.1	15.5	30.5	29.0	45	41	37	33	20	33
2	None	0	−0.1	0	31.2	33.2	32.7	144	123	140	—	—	—
		−0.1	0.05	0	31.7	32.2	31.0	177	156	169	—	—	—
3	None	−0.1	0	0	23.2	33.2	33.5	284	251	255	293	280	284
4	None	0.1	0	0	28.7	28.5	30.2	276	255	255	—	—	—
		0.1	0.1	0	20.0	28.0	29.5	310	289	276	—	—	—
5	None	1	0.15	−0.1	17.2	28.2	29.5	123	99	90	152	169	144
6	None	−0.1	−0.1	−0.2	32.7	32.5	33.2	152	148	144	—	—	—
		0.05	−0.1	−0.1	26.0	30.2	31.2	115	107	107	—	—	—
Mean ± SD		0.13 ± 0.32	−0.01 ± 0.09	0.05 ± 0.06	25.1 ± 6.1	30.7 ± 2.0	30.8 ± 1.6	180.6 ± 84.7	163.2 ± 78.9	163.6 ± 78.1	159.3 ± 106.2	156.3 ± 106.5	153.6 ± 102.6
7	Steroid pulse	0.3	0.05	0.05	21.7	22.7	22.5	123	107	115	198	198	189
8	Steroid pulse	0.7	0.4	0.7	27.2	28.5	29.5	160	152	152	177	206	206
9	Steroid pulse	−0.2	−0.1	−0.1	28.5	29.5	29.2	173	156	148	—	—	—
		0	0	−0.2	26.0	29.2	31.0	175	144	148	—	—	—
10	Oral PSL, STTA	−0.1	0	0.05	22.7	25.2	29.2	94	86	82	86	86	82
Mean ± SD		0.14 ± 0.32	0.07 ± 0.17	0.10 ± 0.31	25.2 ± 2.6	26.9 ± 2.5	28.2 ± 2.9	145.0 ± 31.6	129.0 ± 27.6	129.0 ± 27.0	153.6 ± 48.6	163.3 ± 54.7	159.0 ± 54.8
Total		0.13 ± 0.32	0.01 ± 0.13	−0.01 ± 0.20	25.1 ± 5.1	29.3 ± 2.8	30.0 ± 2.5	167.9 ± 72.6	151.0 ± 67.4	151.2 ± 66.8	156.5 ± 82.6	159.8 ± 84.7	156.3 ± 82.3

Steroid pulse: corticosteroid pulse therapy; PSL: prednisolone; STTA: posterior sub-Tenon injection of triamcinolone acetonide.